Diabetology & Metabolic Syndrome (Nov 2021)

Urine transferrin as an early endothelial dysfunction marker in type 2 diabetic patients without nephropathy: a case control study

  • José Juan Sánchez-Hidalgo,
  • Juan Antonio Suárez-Cuenca,
  • José Juan Lozano-Nuevo,
  • Víctor Hugo García-López,
  • María Graciela Leal-Gutiérrez,
  • Sein Antonio León-Angel,
  • María Leslye Ramírez-Villa,
  • Martha Elena Rodea-Rubio,
  • José Enrique González-Hernández,
  • José Antonio Canela-Mayoral,
  • Eduardo Murillo-Heredia,
  • Eduardo Vera-Gómez,
  • Alejandro Hernández-Patricio,
  • Carlos Ramiro Zamora-Alemán,
  • Gabriela Alexandra Domínguez-Pérez,
  • Juan Ariel Gutiérrez-Buendia,
  • Paul Mondragón-Terán

DOI
https://doi.org/10.1186/s13098-021-00745-1
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background Albumin, along with other proteins, is abnormally eliminated via the urine during early stages of diabetic nephropathy. Moreover, endothelial dysfunction (ED) accompanying early diabetic nephropathy may develop even before microalbuminuria is detectable. Transferrin has a molecular weight comparable to albumin, whereas transferrinuria and microalbuminuria in a 24-h urine sample may comparably reflect early diabetic nephropathy. Whereas transferrin metabolism is related with ED during very early diabetic nephropathy has not been elucidated yet. This case–control study aimed to evaluate the relation between ED and urine transferrin, even before early diabetic nephropathy is present. Methods Patients were enrolled from two study sites in Mexico City: Ticomán General Hospital (healthy controls); and a Specialized Clinic for the Management of the Diabetic Patient (cases). All patients provided written informed consent. The primary endpoint was the correlation between urinary transferrin concentration and ED measured in type 2 diabetic patients without albuminuria. ED was evaluated by ultrasonographic validated measurements, which included carotid intima-media thickness (CIMT) and flow mediated dilation (FMD). Plasma biomarkers included glycated hemoglobin, creatinine, cholesterol and triglycerides, as well as urine albumin, transferrin and evidence of urinary tract infection. Results Sixty patients with type 2 Diabetes Mellitus (t2DM; n = 30) or without t2DM (n = 30), both negative for microalbuminuria, were recruited. The group with t2DM were older, with higher values of HbA1c and higher ED. This group also showed significant differences in urine transferrin and urine/plasma transferrin ratio, as compared with healthy controls (14.4 vs. 18.7 mg/mL, p = 0.04, and 74.2 vs. 49.5; p = 0.01; respectively). Moreover, urine transferrin correlated with higher CIMT values (r = 0.37, p = 0.04), being particularly significant for t2DM population. CIMT also correlated with time from t2DM diagnosis (r = 0.48, p < 0.001) and HbA1c (r = 0.48; p < 0.001). Conclusion Urine transferrin correlated with subclinical atherogenesis in patients with t2DM without renal failure, suggesting its potential to identify cardiovascular risk in patients at very early nephropathy stage without microalbuminuria.

Keywords